Developing nanobodies and sybodies to combat COVID-19
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
List view / Grid view
Three separate studies have identified nanobodies – a miniature form of antibodies found in camelid species – that can bind to the SARS-CoV-2 Spike (S) protein and neutralise the virus in cells.
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
The semi-automated process enabled researchers to make retinal organoid production and selection nearly four times faster.
Scientists have developed a new antibody-drug conjugate (ADC), made from ICAM1, an antibody that targets pancreatic cancer and the cytotoxic drug DM1 (mertansine).
After viral pneumonia in elderly mice, there is an accumulation of dysfunctional tissue-resident memory T cells in the lungs which scientists suggest may drive chronic inflammation and fibrosis.
A new analysis reveals that the course of SARS-CoV-2 infection and the immune response it provokes is completely different in adults and children.
Researchers have used small molecule neural precursor cells to develop midbrain organoids that enable drug effects to be assessed in a complex cell environment.
The newly developed chip includes heart and breast cancer tissues and could be used to predict the cardiac toxicity of chemotherapeutic drugs.
Identify therapeutic effects and adverse responses to compounds earlier in the drug discovery process.
Using lung organoids, researchers have shown that 48 hours after SARS-CoV-2 infection, the innate immune response began.
A simple co-culture assay that can assess anti-tumour T-cell cytotoxicity via luminescence and flow cytometry has been created.
Combining 2D and 3D models with live-cell assays allows monitoring of cell responses in real time and provides important insights about compound treatment effects, biological complexity, and physiological relevance of assay results.
Learn how to perform complex analysis of calcium oscillations and assess cellular and mitochondrial toxicity.
Hannah Balfour explores how genetic variation in G-protein-coupled receptors (GPCRs) and the proteins that regulate the duration of G protein signalling could be contributing to disease and people’s divergent responses to the same therapeutics.
Neurological symptoms have been observed in COVID-19 patients. The link between SARS-CoV-2 and the CNS is critical to developing effective treatments